Successful treatment of intractable hemothorax with recombinant factor VIIa in a nonhemophilic patient
Journal
Journal of the Formosan Medical Association
Journal Volume
105
Journal Issue
9
Pages
765-769
Date Issued
2006
Author(s)
Abstract
Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients with inhibitors. It has also been used to stop bleeding in nonhemophilic patients who fail to respond to conventional treatment. We report a case of catastrophic hemothorax in which bleeding was stopped by administration of rFVIIa. A 68-year-old woman with chronic hepatitis C-related liver cirrhosis was admitted due to pneumonia and parapneumonic effusion. The patient developed hemothorax and hypovolemic shock after thoracentesis. Conventional therapies including tube thoracostomy and transarterial embolization failed to stop the life-threatening bleeding. The bleeding stopped after administration of rFVIIa 100 μg/kg/BW at 2-hour intervals for a total of two doses on the 3rd day of hospitalization. Despite intensive care, however, the patient died due to nosocomial infection and multiple organ failure on the 12th day of hospitalization. Hemothorax in a nonhemophilic patient can be successfully treated with rFVIIa. ? 2006 Elsevier & Formosan Medical Association.
SDGs
Other Subjects
dopamine; hemoglobin; recombinant blood clotting factor 7a; aged; anamnesis; anemia; angiography; article; artificial embolism; bleeding tendency; blood transfusion; case report; cause of death; clinical feature; cryoprecipitate; dose response; drug infusion; fatality; female; hematothorax; hemoglobin determination; hospital infection; human; intensive care unit; international normalized ratio; intubation; laboratory test; liver dysfunction; liver failure; liver function test; multiple organ failure; partial thromboplastin time; physical examination; pleura effusion; pneumonia; thoracocentesis; thrombocytopenia; treatment outcome
Type
journal article